BLISTER CONTAINING A TRANSDERMAL THERAPEUTIC SYSTEM AND A SINGLE DOSE FORM OF ADMINISTRATION

PLAQUETTE ALVEOLAIRE CONTENANT UN SYSTEME THERAPEUTIQUE TRANSDERMIQUE ET UNE FORME GALENIQUE INDIVIDUELLE

English Abstract

A dosage form for medicinal active ingredients in blister
form is characterized in that it contains a transdermal
therapeutic system alongside at least one single-dose
active ingredient form.

French Abstract

Forme galénique se présentant sous la forme d'une plaquette alvéolaire de substances médicinales et caractérisée par le fait qu'elle contient l'un à côté de l'autre un système thérapeutique transdermique et au moins une dose individuelle de substance médicinale.

Claims

-4-

Claims:


1. Blister pack for pharmaceuticals which contains transdermal therapeutic
systems and
single-dose active ingredient forms, characterized in that it comprises at
least one blister form
containing, alongside each other, a single transdermal therapeutic system and
at the same time at
least one single-dose active ingredient form.


2. Blister pack according to Claim 1, characterized in that several blister
forms are joined
together to increase compliance.


3. Blister pack according to Claim 1, characterized in that the individual
blisters are labelled
in the required sequence of use to increase compliance.


4. Blister pack according to Claim 2 or 3, characterized in that blister forms
without
additional single-dose active ingredient forms may also be present.


5. Blister pack according to any one of Claims 1 to 4, characterized in that
the single-dose
active ingredient form is intended for non-transdermal administration of the
active ingredient.

6. Blister pack according to any one of Claims 1 to 5, characterized in that
the single-dose
active ingredient form contains preparations for topical treatment before
and/or after the TTS
administration.


7. Blister pack according to any one of Claims 1 to 6, characterized in that
the single-dose
active ingredient forms contain one or more of the active ingredients
administered via the TTS.

8. A blister pack for pharmaceuticals comprising an integral substrate having
at least two
receptacles formed thereon, a transdermal therapeutic system contained in a
first of the
receptacles and a single-dose pharmaceutical contained in a second of the
receptacles, whereby a
user of the blister pack is reminded that the user is to use the contents of
the first and the second
receptacles according to a preset regimen.


9. The blister pack according to Claim 8, further comprising indicia adjacent
the receptacles
for additionally reminding the user of the blister pack of the preset
regiment.


-5-

10. The blister pack according to Claim 8 or 9, wherein the single-dose
pharmaceutical is for
non-transdermal administration.


11. The blister pack according to Claim 8 or 9, wherein the single-dose
pharmaceutical is for
topical application before and/or after administration of the transdermal
therapeutic system.


12. The blister pack according to Claim 10, wherein the single-dose
pharmaceutical contains
at least one pharmaceutical also administered by the transdermal therapeutic
system.

Description

CA 02336711 2001-01-05

The invention relates to a dosage form for medicinal active
ingredients in blister form, which makes it possible to
administer simultaneously a transdermal therapeutic system
(TTS) and at least one single-dose active ingredient.

It is customary in hormone replacement therapy to combine
administration of the basic hormone with administration of
another hormone in order to avoid side effects. This
applies, for example, to oestradiol administration, which
takes place with administration of a gestagen. Since long-
term, continuous administration of the basic hormone is
desired, a suitable administration form has proved to be
the transdermal therapeutic system (TTS), with which the
active ingredient is delivered to the skin in controlled
manner via a defined contact area of an active ingredient
reservoir. The system preferably comprises a pressure-
sensitive adhesive. if discontinuous concomitant medication
with another hormone is desired, this usually takes place
in tablet form. The tablets are normally stored separately
and can be manipulated in accordance with the
administration schedule only with difficulty. This type of
dosage forms is thus extremely unfavourable for patient
compliance.

It was therefore an object of the invention, for compliance
reasons, to create a suitable packaging procedure for
simultaneous administration of medicinal active ingredients
via the transdermal and non-transdermal route. This was
intended to ensure that the patient is aided, by an
appropriate design of packaging, in implementing where
possible intake of single doses at defined times.


CA 02336711 2001-01-05

- 2 -

The achievement of the object has now been found in a
blister form which, besides the TTS, contains at least one
single-dose active ingredient form. The TTS is packed
individually in a blister but may also be fixed to the
dosage form in another way, such as, for example, by means
of the pressure-sensitive adhesive contact area.
Accommodation in a blister is also the method of choice for
the single-dose active ingredient form, which is preferably
a tablet, it also being possible, of course, to conceive
other attachment mechanisms.

Joining together several blister forms has proved
advantageous for longer-term administration. This means for
the patient that his administration regimen is fixed
accurately and unambiguously for weeks. The series of
blister forms may perfectly well include those which have
no single-dose active ingredient form, if required for
therapeutic reasons.

The single-dose active ingredient form is usually designed
for non-transdermal administration. Otherwise, care must be
taken that bolus-like release is ensured. Besides or in
place of systemic active ingredients it is possible for the
single-dose active ingredient form also to contain
preparations for topical pretreatment and/or after-
treatment of the TTS administration area. These
preparations may, for example, improve the skin
permeability of the active ingredient from the TTS or
prevent or even reverse harmful skin changes after
administration of the TTS. Last but not least, the single-
dose active ingredient form may also contain one or more
TTS active ingredients in order to cover the TTS lag time
or generate an additional plasma peak required by the
circadian rhythm.


CA 02336711 2001-01-05

- 3 -

The following example, illustrated by Fig. 1, summarizes
the compliance-ensuring aspects of the novel dosage form
with the aid of a unit composed of eight TTS 1 to 8, which
is provided for a treatment period of 28 days. 9 indicates
the single-dose active ingredient forms, none of which are
contained in 1-4.
The following table reflects the course of administration
for an oestrogen/gestagen treatment:

No. of the Duration of wearing the
blister form blister form
Oes treatment Blister No. 1 1st, 2nd, 3rd day
without Blister No. 2 4th, 5th, 6th, 7th day
gestagen Blister No. 3 8th, 9th, 10th day
administration Blister No. 4 11th, 12th, 13th, 14th day
Oes treatment Blister No. 5 15th, 16th, 17th day
in combination Blister No. 6 18th, 19th, 20th, 21st day
with gestagen Blister No. 7 22nd, 23rd, 24th day
administration Blister No, 8 25th, 26th, 27th, 28th day
in tablet form

A gestagen-free treatment period of 14 days is followed by
provision of a gestagen administration for each day of the
TTS administration (alternating three and four days) in the
last two weeks.

As the example illustrates, the invention provides a
reliable means for permanently improving the compliance of
patients on TTS administration with an additional single-
dose active ingredient form.

The compliance can be increased by joining several blister
forms together or labelling the individual blisters in the
required sequence of use.

Representative Drawing